Objectives: Patients with severe subarachnoid haemorrhage (SAH) often suffer from complications with delayed cerebral ischaemia (DCI) due to vasospasm that is difficult to identify by clinical examination. The purpose of this study was to monitor seizures and to measure cerebrospinal fluid (CSF) concentrations of neurofilament light (NFL) and tau, and to see whether they could be used for predicting preclinical DCI.
| INTRODUCTION
Subarachnoid haemorrhage (SAH) is a severe condition with high morbidity and mortality with an incidence of 9 per 100 000. 1 The most devastating complication of SAH is delayed cerebral ischaemia (DCI).
DCI is defined as new focal or global neurological deficits and new cerebral infarction on computed tomography (CT) that is not caused by rebleeding or acute hydrocephalus. 2 Signs of DCI occur in about 30%
of patients, typically appear between days 4 and 10 following SAH and are the major causes of morbidity and death. 3, 4 The pathophysiology of DCI is not fully understood, but intracranial arterial vasospasm probably plays a role. A major challenge in the management of SAH is early identification of DCI, thereby enabling therapeutic intervention.
Acute symptomatic seizures (ASS) have been reported to occur in 6%-24% of SAH cases. 5, 6 Continuous EEG (cEEG) allows monitoring of patients with acute aneurysmal subarachnoid haemorrhage for detection of non-convulsive seizures and non-convulsive status epilepticus.
Both clinical and electrographic seizures (ES) are believed to have a negative impact on the outcome. 7 Continuous EEG has also been used for surveillance and early recognition of DCI. 8 Significant efforts have been made to study different biomarkers as potential tools for predicting vasospasm and outcome after SAH. In this study, we wished to determine whether the occurrence of ASS is a clinical marker of impeding DCI and to study the association between CSF concentrations of NFL and tau and DCI in patients with acute SAH.
| MATERIALS AND METHODS

| Study population
The study was a prospective observational study. Patients with SAH admitted to the Neurointensive Care Unit (NICU) at Uppsala
University Hospital between July 2015 and July 2016 were consecutively included.
Inclusion criteria were spontaneous SAH with an aneurysm treated with endovascular coiling. Exclusion criteria were surgical treatment of the aneurysm, a previous history of neurological disease including epilepsy, and severe traumatic brain injury.
On admission, patients were evaluated clinically and investigated with CT including CT angiography. The severity of the clinical condition on admission was graded according to Hunt and Hess. 14 The amount of bleeding in the first CT was graded according to the Fisher scale. 15 Clinical seizures were systematically recorded and considered acute symptomatic if they appeared during the acute phase of the brain insult. 16 The patients were treated with neurointervention within the first 48 hours to eliminate the source of bleeding. The rest of the treatment was performed according to our NICU protocols for SAH. 17 In summary, unconscious patients were given artificial ventilation and external ventricular drainage (EVD) to monitor and treat the intracranial pressure (ICP). Sedation was carried out with propofol and opioids.
Nimodipine was administered intravenously or in the nasogastric tube. analysed. Amplitude-integrated EEG (aEEG) trend (based on F3, F4, P3 and P4) was used for seizure detection, and all suspected seizures were verified or falsified using the raw EEG. Rhythmic or epileptiform activity with spatiotemporal evolution lasting for at least 10 seconds was regarded as electrographic seizure activity. 18 (range 340-19100 ng/L) and NFL10 18014 ± 17321 ng/L (range 1850-73100). For details concerning each patient, see Table 1 . There was no statistically significant association between DCI and any of the other variables (H&H, ASS, ES, NFL4, NFL10, tau4 and tau10), see Table 2 .
Delayed cerebral ischaemia was observed in 7 patients (37%
| DISCUSSION
Many attempts to predict DCI depending on a single factor have failed; therefore, we carried out a prospective study to examine the use of cEEG and CSF concentrations of NFL and T-tau. Convulsive and non-convulsive seizures are common complications of SAH. The true frequency of NCS is unknown but has been described in 8% to 30% 19, 20 of comatose patients. It has been shown that seizures (clinical and electrographic) independently predict poor outcome after SAH, but a significant relation to vasospasm has never been established. In the present study, we used continuous EEG monitoring for 72 hours early in the disease course and only found one patient with electrographic seizures. Altogether, seizures were noted in 36% of the patients, but their presence could not predict impending DCI.
Reports of NFL in relation to SAH and DCI are very scarce in the literature. 9 One study 11 reported a significant increase in CSF NFL in SAH patients with secondary events. In our study, NFL showed an increase in all patients, but we were not able to detect any association between levels of concentrations of NFL and poor outcome with DCI.
In previous studies, 21, 22 it has been shown that SAH was associated with a significant increase in CSF tau measured at days 1 and 2 and that the increase correlated to extent of brain injury and poor clinical outcome. A delayed peak, however, preceding the occurrence of clinical vasospasm did not follow this acute peak. We could not confirm these findings. On the contrary, there was no correlation between tau at day 4 and severity of SAH. This discrepancy could be attributed to the rather small numbers of patients in both studies and measurements at different time points. Using tau ratio, a factor that may reflect ongoing brain damage and risk of DCI, an increase was noted in a majority of the patients who developed DCI (5 of 7) during the first 2 weeks. We believe that changes in tau levels between days 4 and 10 could thus be a sign of excessive cortical damage related to the development of DCI.
The exact relationship between tau levels and brain damage is not possible to distinguish from our data, and several explanations are possible.
The primary brain damage may cause both increase in tau and provoke DCI. Furthermore, DCI alone may cause an extra increase in tau, and finally, DCI may cause secondary brain damage resulting in tau elevation.
We could not detect an increase in tau ratio in the patients that developed DCI later than day 12, most probably due to the limitation of sampling time.
The pathophysiologic mechanism underlying DCI is probably multifactorial and is not fully understood. It has long been argued that cerebral vasoconstriction is the major contributing factor. Other additional mechanisms include spreading depression and "early brain damage," referring to the damage that occurs to the brain in the first 72 hours after the initial bleeding. 23 While this takes place before the onset of DCI, it seems probable that the physiological changes increase the energy demand and thereby influence the likelihood of secondary complications such as DCI. With this view, a sensitive CSF biomarker for cortical or neuronal damage would be a valuable tool in treatment aimed at avoiding DCI. There were 3 cases with bacterial meningitis and 2 with sepsis. Bacterial meningitis may increase NFL concentration in CSF, but CSF T-tau is unaffected which corroborates with our data. 24, 25 The increase in CSF NFL in meningitis has been interpreted as a sign of neuronal injury regardless of the presence or absence of neurological sequelae. There are, to our knowledge, no studies on CSF NFL or tau in sepsis without meningitis.
Our study has several limitations. First, the small number of patients restricts the statistical power of the results. Nonetheless, there were statistically significant data supporting the hypothesis that increased tau ratio could be a valuable biomarker for DCI. However, verification of the results in a larger cohort is required in order to be able to rely on the clinical utility of this approach. Other constraints include the presence of comorbidities and that the use of sedatives and antiepileptic medication was not controlled. This most certainly influenced the EEG results and theoretically could have affected levels of tau and NFL. In the literature, however, there are no data on the impact of sedatives and antiepileptic drugs on biomarkers such as NFL and tau.
Furthermore, the optimal timing of measuring CSF biomarkers is not fully established. We chose days 4 and 10 as DCI typically appears between 4 and 10 days after SAH, but more frequent sampling might have disclosed important changes. In summary, acute symptomatic seizures are common in SAH, but their presence does not predict DCI. It may be important to monitor continuous measurements of CSF tau concentrations in patients with SAH during intensive care.
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